US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Stage

0.3754

+0.0000

Volume:- -

Turnover:- -

Market Cap:10.85M

PE:-0.11

High:0.3754

Open:0.3754

Low:0.3754

Close:0.3754

Loading ...

Overview Company News Filings

Plus Therapeutics' Brain Cancer Therapy Shows Promise in Early-Stage Study; Shares Rise

MT Newswires Live

AstraZeneca's Imfinzi-Based Regimen Shows Improved Event-Free Survival In Early-Stage Gastric Cancer Patients

Black Cowboys Take Center Stage: 8 Seconds Rodeo Expands for Its Biggest Year Yet!

Cautious Hold Rating on Adicet Bio Amid Early-Stage Clinical Developments and Uncertain Outcomes

Trump’s Strategic Bitcoin Reserve Sets the Stage for America’s Crypto Leadership

Press Release: Elutia Announces Fourth Quarter and Full Year 2024 Financial Results: Strong Demand for EluPro(TM) in Pilot Launch Sets the Stage for Full Commercial Roll-Out

Cautious Optimism: Hold Rating for Fate Therapeutics Amid Early-Stage Progress and Market Uncertainties

Arrowhead Pharmaceuticals Presents Data on Two Clinical-Stage Candidates for Obesity Treatment

MT Newswires Live

Arrowhead Pharmaceuticals Showcases Two Clinical-Stage RNAi-Based Candidates to Treat Obesity and Metabolic Diseases

Sensus Healthcare to Showcase Commercial and Late-Stage Products at the American Academy of Dermatology Annual Meeting

Hold Rating for Fate Therapeutics Amid Early-Stage Pipeline Uncertainty and Cautious Cash Position

AI in China's Healthcare Still at Nascent Stage -- Market Talk

RTG Mining Says Associate Enters Partnership With Glencore to Finance Stage 1 of Philippines Copper-Gold Project; Shares Surge 37%

MT Newswires Live

Plume and Cicada Launch Early-Stage Investment Program for RWAfi Projects

Amgen (NASDAQ:AMGN) Enters Late-Stage Testing on Weight Loss Drug

Slowing Construction and Rising Capital Flows Set Stage for Life Sciences Market Rebound

Auddia to Present at SXSW Conference on Podcast Industry Stage

WISeKey WISeID Provides Healthcare Security with Decentralized Digital Identities

Best Cryptos to Join for Short Term Profits This Month: Qubetics, Tezos & Terra Classic Set the Stage for Massive Gains

Nvidia 15% Drop Sets Stage for a Rebound, Analysts Predict

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/SSI/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"SSI","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SSI\",,,,,undefined,":{"symbol":"SSI","market":"US","secType":"STK","nameCN":"Stage","latestPrice":0.3754,"timestamp":1588968000000,"preClose":0.3754,"halted":3,"volume":0,"delay":0,"floatShares":20307519,"shares":28911336,"eps":-3.332056,"marketStatus":"Halted","change":0,"latestTime":"04-02 19:13:49 EDT","open":0.3754,"high":0.3754,"low":0.3754,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.332056,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1743638400000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":998884800000,"exchange":"NYSE","adjPreClose":0.3754,"dividendRate":0.133191,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SSI\",,,,,undefined,":{"symbol":"SSI","floatShares":20307519,"roa":"-3.54%","roe":"-44.60%","lyrEps":-3.1264,"shares":28911336,"dividePrice":0.05,"high":0.3754,"amplitude":0,"preClose":0.3754,"low":0.3754,"week52Low":0.27,"pbRate":"0.07","week52High":9.5,"institutionHeld":0.5253,"latestPrice":0.3754,"eps":-3.332056,"divideRate":0.133191,"volume":0,"delay":0,"ttmEps":-3.332056,"open":0.3754,"prevYearClose":8.12},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SSI\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2517802344","title":"Plus Therapeutics' Brain Cancer Therapy Shows Promise in Early-Stage Study; Shares Rise","url":"https://stock-news.laohu8.com/highlight/detail?id=2517802344","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517802344?lang=en_us&edition=fundamental","pubTime":"2025-03-07 21:15","pubTimestamp":1741353305,"startTime":"0","endTime":"0","summary":"Plus Therapeutics  said Friday that its experimental drug, rhenium obisbemeda, demonstrated a median overall survival of 11 months in an early-stage study, outperforming the standard of care of 8 months for recurrent glioblastoma, a type of brain tumor.The clinical-stage company said that the study showed no dose-limiting toxicity, and that the majority of adverse events were unrelated to the treatment.Plus Therapeutics said that, based on these results, it is currently enrolling patients in a mid-stage trial at medical centers.Shares of the company climbed as much as 40% in recent premarket activity on Friday.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ","SSI","PSTV","BK4139"],"gpt_icon":0},{"id":"2517388304","title":"AstraZeneca's Imfinzi-Based Regimen Shows Improved Event-Free Survival In Early-Stage Gastric Cancer Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2517388304","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517388304?lang=en_us&edition=fundamental","pubTime":"2025-03-07 20:54","pubTimestamp":1741352061,"startTime":"0","endTime":"0","summary":"On Friday, AstraZeneca Plc  released high-level results from the MATTERHORN Phase 3 trial evaluatingImfinzi as a perioperative treatment for patients with resectable Stage II-IVA gastric and gastroesophageal junction  cancers.The trial showed that perioperative treatment with Imfinziin combination with standard-of-care FLOT  chemotherapy demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of event-free survival .Also Read: AstraZeneca’s Imfinzi Perioperative Regimen Shows Improved Survival Outcomes In Bladder Cancer Patients. The trial evaluated this regimen versus perioperative chemotherapy alone for patients with resectable, early-stage and locally advanced  gastric and gastroesophageal junction  cancers.A strong trend was observed for the secondary endpoint of overall survival  in favor of theImfinzi-based regimen. The trial will follow OS, which will be formally assessed at the final analysis.Gastric cancer is the fifth leading cau","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/astrazenecas-imfinzi-based-regimen-shows-125421014.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4588","LU2417539215.USD","SSI","BK4007","BK4585","LU0889565916.HKD","LU2462157665.USD","LU0320765992.SGD","LU1829250122.USD","LU2236285917.USD","LU2456880835.USD","AZN","LU0109394709.USD","OS","BK4097","BK4568"],"gpt_icon":0},{"id":"2517148136","title":"Black Cowboys Take Center Stage: 8 Seconds Rodeo Expands for Its Biggest Year Yet!","url":"https://stock-news.laohu8.com/highlight/detail?id=2517148136","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517148136?lang=en_us&edition=fundamental","pubTime":"2025-03-07 20:00","pubTimestamp":1741348800,"startTime":"0","endTime":"0","summary":"PORTLAND, Ore., March 7, 2025 /PRNewswire/ -- The 8 Seconds Rodeo returns for its third and most electrifying year, expanding to two major cities and celebrating today's Black cowboys on a national stage. On June 15th in Portland, OR , and October 11th in Philadelphia, PA , this groundbreaking rodeo will bring together 8,000 fans per event for a night of high-stakes competition, Black culture, and world-class entertainment.This year's rodeo will feature an intense lineup of events, including Bull Riding, Bareback Bronco Riding, Barrel Racing, and Mutton Bustin', with top Black rodeo athletes from around the country competing for $60,000 in prize money. Hosted by comedienne X Mayo, the 8 Seconds Juneteenth Rodeo delivers more than just action—it's a powerful, physically and spiritually moving experience that showcases the grit, talent, and heritage of Black rodeo athletes.Elite Rodeo Competition– Featuring Bull Riding, Bareback Bronco Riding, Barrel Racing, and Mutton Bustin' with a $60","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/black-cowboys-center-stage-8-120000402.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/black-cowboys-center-stage-8-120000402.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["DGE.UK","DEO","BK4588","SSI","BK4169","BK4585"],"gpt_icon":0},{"id":"2517485147","title":"Cautious Hold Rating on Adicet Bio Amid Early-Stage Clinical Developments and Uncertain Outcomes","url":"https://stock-news.laohu8.com/highlight/detail?id=2517485147","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517485147?lang=en_us&edition=fundamental","pubTime":"2025-03-07 19:19","pubTimestamp":1741346358,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Edward White has reiterated their neutral stance on ACET stock, giving a Hold rating today. Edward White has given his Hold...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/cautious-hold-rating-on-adicet-bio-amid-early-stage-clinical-developments-and-uncertain-outcomes?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/cautious-hold-rating-on-adicet-bio-amid-early-stage-clinical-developments-and-uncertain-outcomes?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SSI"],"gpt_icon":0},{"id":"2517347129","title":"Trump’s Strategic Bitcoin Reserve Sets the Stage for America’s Crypto Leadership","url":"https://stock-news.laohu8.com/highlight/detail?id=2517347129","media":"CoinMarketCap","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517347129?lang=en_us&edition=fundamental","pubTime":"2025-03-07 12:39","pubTimestamp":1741322363,"startTime":"0","endTime":"0","summary":"You can also read this news on COINTURK NEWS: Trump’s Strategic Bitcoin Reserve Sets the Stage for America’s Crypto Leadership. The establishment of the United States’ Strategic Bitcoin Reserve, following a presidential decree signed by Donald Trump, signifies a pivotal step for the future of the cryptocurrency market. David Sacks emphasized that the U.S. does not plan to sell Bitcoin but aims to hold it as a store of value. He described the forthcoming reserve as a “digital Fort Knox,” reinforcing Bitcoin’s status as “digital gold” and symbolizing America’s approach to cryptocurrencies.Following the announcement of Trump’s presidential decree for the Strategic Bitcoin Reserve, Senator Cynthia Lummis stated on X that the U.S. will become the center of Bitcoin and cryptocurrencies. She noted that the U.S. is rapidly progressing towards leading the cryptocurrency market. Lummis expressed that “America is becoming the capital of Bitcoin and cryptocurrencies,” asserting that these developm","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://coinmarketcap.com/community/articles/67ca787fa0dc90660e62af1e/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"coinmarketcap_highlight","symbols":["TON.USD.HKCC","TON.USD.CC","APT.USD.HKCC","BTC.USD.HKCC","BTC.USD.CC","BK4585","APT.USD.CC","BK4594","SSI","BK4601","BK4588"],"gpt_icon":1},{"id":"2517118230","title":"Press Release: Elutia Announces Fourth Quarter and Full Year 2024 Financial Results: Strong Demand for EluPro(TM) in Pilot Launch Sets the Stage for Full Commercial Roll-Out","url":"https://stock-news.laohu8.com/highlight/detail?id=2517118230","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517118230?lang=en_us&edition=fundamental","pubTime":"2025-03-07 05:05","pubTimestamp":1741295100,"startTime":"0","endTime":"0","summary":"Elutia Announces Fourth Quarter and Full Year 2024 Financial Results: Strong Demand for EluPro in Pilot Launch Sets the Stage for Full Commercial Roll-Out. -- Overall BioEnvelope sales up 18%, with same-center sales increasing 65% following EluPro commercialization --. SILVER SPRING, Md., March 06, 2025  -- Elutia Inc.  , a pioneer in drug-eluting biomatrix technologies, today provided a business update and financial results for the fourth quarter and full year ended December 31, 2024.-- Strong Initial Market Uptake for EluPro: Since its pilot launch in the. fourth quarter, EluPro has been utilized across all major cardiac. implantable electronic device  brands, accounting for over 30% of. BioEnvelope  sales in the quarter. Early adoption in. -- Robust Market Expansion: Elutia closed 2024 with 67 approved EluPro. accounts, averaging more than 15 new approvals per month through Value. Analysis Committees . The Company now has approximately 100. -- Group Purchasing Agreements: Sales grow","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SSI","BK4555","ELUT","TM","BK4604","BK4139","03160","BK4585","BK4099","BK4588"],"gpt_icon":0},{"id":"2517193749","title":"Cautious Optimism: Hold Rating for Fate Therapeutics Amid Early-Stage Progress and Market Uncertainties","url":"https://stock-news.laohu8.com/highlight/detail?id=2517193749","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517193749?lang=en_us&edition=fundamental","pubTime":"2025-03-07 01:26","pubTimestamp":1741281978,"startTime":"0","endTime":"0","summary":"Fate Therapeutics (FATE – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Michael Ulz from M...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/cautious-optimism-hold-rating-for-fate-therapeutics-amid-early-stage-progress-and-market-uncertainties?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/cautious-optimism-hold-rating-for-fate-therapeutics-amid-early-stage-progress-and-market-uncertainties?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SSI","PRGS","FATE"],"gpt_icon":0},{"id":"2517031165","title":"Arrowhead Pharmaceuticals Presents Data on Two Clinical-Stage Candidates for Obesity Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2517031165","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517031165?lang=en_us&edition=fundamental","pubTime":"2025-03-06 22:48","pubTimestamp":1741272537,"startTime":"0","endTime":"0","summary":"Arrowhead Pharmaceuticals  said Thursday it has presented preclinical data supporting two RNA-interference-based investigational therapeutics it is developing, with the potential to reduce body weight and fat mass and preserve lean muscle mass compared with currently approved obesity therapies.Data from its ARO-INHBE candidate preclinical results showed a 19% suppression in body weight gain relative to vehicle controls, while data from its ARO-ALK7 candidate preclinical results showed a 39% suppression, the company said.Arrowhead is currently conducting phase 1/2 clinical studies of the two candidates. The company expects initial data from its ARO-INHBE study year-end 2025, and anticipates dosing in the ARO-ALK7 study to begin in the second quarter with initial data from the single-ascending dose portion of the study possible also by year-end 2025.The company presented the data at the RNA Leaders Europe Congress 2025 held March 4-6 in Basel, Switzerland.Price: 16.89, Change: -0.46, Per","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4585","BK4139","ARWR","BK4588","SSI"],"gpt_icon":0},{"id":"2517716889","title":"Arrowhead Pharmaceuticals Showcases Two Clinical-Stage RNAi-Based Candidates to Treat Obesity and Metabolic Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2517716889","media":"Business Wire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517716889?lang=en_us&edition=fundamental","pubTime":"2025-03-06 21:45","pubTimestamp":1741268700,"startTime":"0","endTime":"0","summary":"- ARO-INHBE and ARO-ALK7 both target a known pathway that signals the body to store fat in adipose tissue with a novel mechanism of action that may better preserve lean muscle mass compared to currently approved obesity therapies. - Data highlight Arrowhead’s leadership in the use of RNA interference to potentially treat Obesity. DIO mice treated with an ALK7 siRNA exhibit a 39% suppression in body weight gain relative to controls. Adipose ALK7 silencing reduced fat mass by 50% while preserving lean mass. Similar to INHBE silencing in hepatocytes, ALK7 silencing in adipocytes enhanced catecholamine sensitivity, increasing lipid mobilization and oxidation, which was not associated with liver","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/arrowhead-pharmaceuticals-showcases-two-clinical-134500669.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","SSI","ARWR","BK4585","BK4588"],"gpt_icon":0},{"id":"2517315789","title":"Sensus Healthcare to Showcase Commercial and Late-Stage Products at the American Academy of Dermatology Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2517315789","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517315789?lang=en_us&edition=fundamental","pubTime":"2025-03-06 21:00","pubTimestamp":1741266000,"startTime":"0","endTime":"0","summary":"Full line of SRT products along with innovative pre-commercial products including portable lesion detection and TransDermal Infusion to be featured in a brand-new, A.I.-focused environment at Booth #2451. At Booth #2451, Sensus invites attendees to \"The A.I. Experience,\" its brand new, futuristic, technology-focused environment specially designed to spotlight the Company’s innovations and technologies. Among the showcased products will be the SRT-100 Vision, the only FDA-cleared IG-SRT that’s increasingly being recognized by dermatologists as the non-surgical solution of choice for treating non-melanoma skin cancer and keloids. The booth will also showcase Sensus’ new prototype handheld ultrasound device, designed to help clinicians identify skin lesions and enhance practice efficiency, and its work-in-process TransDermal Infusion  product with Sentinel IT Solutions capabilities.As part of its commitment to customer engagement, Sensus Healthcare will be hosting an invitation-only dinne","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/sensus-healthcare-showcase-commercial-stage-130000060.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SSI","BK4107","TDI","BK4106","BK4082","BK4117","SRTS","SRT","AFG","BK4226"],"gpt_icon":0},{"id":"2517156902","title":"Hold Rating for Fate Therapeutics Amid Early-Stage Pipeline Uncertainty and Cautious Cash Position","url":"https://stock-news.laohu8.com/highlight/detail?id=2517156902","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517156902?lang=en_us&edition=fundamental","pubTime":"2025-03-06 19:57","pubTimestamp":1741262233,"startTime":"0","endTime":"0","summary":"Needham analyst Gil Blum has maintained their neutral stance on FATE stock, giving a Hold rating today. Gil Blum has given his Hold rating due to a...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/hold-rating-for-fate-therapeutics-amid-early-stage-pipeline-uncertainty-and-cautious-cash-position?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/hold-rating-for-fate-therapeutics-amid-early-stage-pipeline-uncertainty-and-cautious-cash-position?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SSI","FATE"],"gpt_icon":0},{"id":"2517664185","title":"AI in China's Healthcare Still at Nascent Stage -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2517664185","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517664185?lang=en_us&edition=fundamental","pubTime":"2025-03-06 14:33","pubTimestamp":1741242780,"startTime":"0","endTime":"0","summary":"0633 GMT - The use of AI in China's healthcare sector is nascent and expected to contribute up to only 2.5% of incremental revenue to the country's pharmaceutical and healthcare-services sector by 2028, HSBC Qianhai's Linda Shu says in a note. However, with major players like Tencent, Alibaba and JD.com entering the space, AI's impact is growing given its use in saving costs and addressing resource shortages, says the head of China healthcare research. In the near term, breakthroughs in medical imaging, diagnostics and hospital management could drive AI adoption, while in the long term, smart hospitals and personalized care may become mainstream, she says. Pharmaceutical companies, medical-device manufacturers and agile startups are well-positioned to capture market share by building AI-driven ecosystems and forging strategic partnerships, she adds. ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0821914370.USD","LU0251143458.SGD","LU1008478684.HKD","LU1688375341.USD","BK4527","LU1046421795.USD","BK4122","LU2226246903.HKD","BK4524","HCSG","LU0880133367.SGD","LU0348814723.USD","SSI","BABA","LU0918141705.HKD","BK4531","BK4558","LU1051768304.USD","BK4581","BK4548","LU1242518857.USD","BK4534","BK4220","BK4502","BK4505","BK4554","BK4588","BK4575","LU0052756011.USD","LU0067412154.USD","LU0979878070.USD","LU1048596156.SGD","LU1105468828.SGD","IE00BFMHRM44.USD","BK4579","BK4587","LU1242518931.SGD","LU1267930227.SGD","BK4565","BK4535","BK4585","IE00B0JY6N72.USD","LU0918141887.USD","LU1282648689.USD","09988","BK4137","LU0128525689.USD","LU0797268264.HKD","LU1823568750.SGD","BK4543"],"gpt_icon":0},{"id":"2517590262","title":"RTG Mining Says Associate Enters Partnership With Glencore to Finance Stage 1 of Philippines Copper-Gold Project; Shares Surge 37%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517590262","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517590262?lang=en_us&edition=fundamental","pubTime":"2025-03-06 12:59","pubTimestamp":1741237179,"startTime":"0","endTime":"0","summary":"RTG Mining  said its associate firm Mt. Labo Exploration and Development entered a strategic partnership with Glencore International to finance the first stage of the Mabilo copper-gold project in the Philippines, according to a Thursday Australian bourse filing.The parties entered into a binding term sheet for a financing facility for a total of up to $30 million in three tranches, as well as an offtake agreement for all stage one products on market terms.The facility provides funding for the estimated development budget, together with a further $5 million for any cost overruns and working capital needs.RTG's share in the project cash flow from stage one direct shipping operation is expected to be in the order of 50% of total proceeds, the filing said.The firm's shares rose almost 37% in recent trading on Thursday.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["RTG.AU","BK7104","SSI"],"gpt_icon":1},{"id":"2517242509","title":"Plume and Cicada Launch Early-Stage Investment Program for RWAfi Projects","url":"https://stock-news.laohu8.com/highlight/detail?id=2517242509","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517242509?lang=en_us&edition=fundamental","pubTime":"2025-03-06 05:30","pubTimestamp":1741210203,"startTime":"0","endTime":"0","summary":"New York City, United States, March 5th, 2025, Chainwire Plume, the first L1 Chain purpose-built for Real World Asset Finance (RWAfi), and Cicada, ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/newswire/plume-and-cicada-launch-early-stage-investment-program-for-rwafi-projects?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/newswire/plume-and-cicada-launch-early-stage-investment-program-for-rwafi-projects?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SSI"],"gpt_icon":0},{"id":"2517947696","title":"Amgen (NASDAQ:AMGN) Enters Late-Stage Testing on Weight Loss Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2517947696","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517947696?lang=en_us&edition=fundamental","pubTime":"2025-03-06 01:34","pubTimestamp":1741196086,"startTime":"0","endTime":"0","summary":"We know that weight loss drugs have been big winners for the companies that produce them. And now, biotech stock Amgen ($AMGN) looks to get in on t...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/amgen-nasdaqamgn-enters-late-stage-testing-on-weight-loss-drug?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/amgen-nasdaqamgn-enters-late-stage-testing-on-weight-loss-drug?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SSI","IE00B2B36J28.USD","SG9999001440.SGD","TQQQ","SQQQ","LU2242652126.USD","IE0009355771.USD","LU0109394709.USD","LU2242646821.SGD","NDAQ","LU1057294990.SGD","BK4566","LU1061106388.HKD","IE00B4R5TH58.HKD","QID","LU0289739699.SGD","LU0868494617.USD","LU2210149790.SGD","BK4533","IE00BJT1NW94.SGD","LU0122379950.USD","IE0002141913.USD","LU2095319765.USD","LU0320765992.SGD","IE00BFTCPJ56.SGD","IE00BGHQF748.EUR","BK4581","AMGN","IE00B64PRP62.GBP","LU1983299246.USD","USAW.SI","NQmain","MNQmain","BK4112","LU1023059063.AUD","QLD",".IXIC","LU0889565916.HKD","USJW.SI","NVIW.SI","LU1571399168.USD","TSYW.SI","LU2210150020.SGD","BK4588","BK4139","BK4599","LU0058720904.USD","PSQ","IE00B3QW5Z07.USD"],"gpt_icon":0},{"id":"2517949650","title":"Slowing Construction and Rising Capital Flows Set Stage for Life Sciences Market Rebound","url":"https://stock-news.laohu8.com/highlight/detail?id=2517949650","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517949650?lang=en_us&edition=fundamental","pubTime":"2025-03-06 00:00","pubTimestamp":1741190400,"startTime":"0","endTime":"0","summary":"Cushman & Wakefield releases its 2025 Life Sciences Update. CHICAGO, March 05, 2025----The life sciences real estate market is undergoing significant changes as supply outpaces demand, influencing rental growth, vacancy rates, and investment trends.The overall vacancy rate across major life sciences markets reached 20.5% in Q4 2024, up 250 basis points from Q2 2024. The total U.S. market saw negative net absorption for the second consecutive year, though key markets like Boston, Chicago, and Los Angeles-Orange County posted positive absorption in 2024.The U.S. life sciences construction pipeline has contracted significantly, with just 2 million square feet  expected to be delivered beyond 2025, down from 16 msf currently under construction. At present, supply continues to exceed demand, leading to softer asking rent growth and higher vacancy rates across key markets. However, a slowdown in new construction is expected to restore balance between supply and demand.\"Despite short-term cha","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/slowing-construction-rising-capital-flows-160000726.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4079","CWK","SSI"],"gpt_icon":0},{"id":"2517997220","title":"Auddia to Present at SXSW Conference on Podcast Industry Stage","url":"https://stock-news.laohu8.com/highlight/detail?id=2517997220","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517997220?lang=en_us&edition=fundamental","pubTime":"2025-03-05 19:00","pubTimestamp":1741172400,"startTime":"0","endTime":"0","summary":"Presentation entitled “Podcast Apps Need to Step It Up” sponsored by Auddia’s partner Sounds Profitable. BOULDER, Colo., March 05, 2025  -- Auddia Inc.   , a technology company that has built a proprietary AI platform for audio identification and classification to reinvent how consumers engage with audio, today announced it will be presenting at this year’s SXSW with its partner Sounds Profitable.The presentation, entitled “Podcast Apps Need to Step It Up”, will outline how the company views the podcast industry’s financial landscape, some tactics and strategies it has tried in order to improve that landscape for podcast listeners and creators, and provide further ideas for discussion with industry leaders.subscription based, ad free listening on any AM/FM radio station","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/auddia-present-sxsw-conference-podcast-110000239.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["AUUDW","SSI","AUUD","BK4023"],"gpt_icon":0},{"id":"2517688559","title":"WISeKey WISeID Provides Healthcare Security with Decentralized Digital Identities","url":"https://stock-news.laohu8.com/highlight/detail?id=2517688559","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517688559?lang=en_us&edition=fundamental","pubTime":"2025-03-05 14:00","pubTimestamp":1741154400,"startTime":"0","endTime":"0","summary":"WISeKey WISeID Provides Healthcare Security with Decentralized Digital Identities Geneva, Switzerland, March 5, 2025 –WISeKey International Holding Ltd (“WISeKey”) (SIX: WIHN, NASDAQ: WKEY), a leading","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/05/3037100/0/en/WISeKey-WISeID-Provides-Healthcare-Security-with-Decentralized-Digital-Identities.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SSI","BK4141","WKEY","BK4137","BK4565","HCSG"],"gpt_icon":1},{"id":"2517958017","title":"Best Cryptos to Join for Short Term Profits This Month: Qubetics, Tezos & Terra Classic Set the Stage for Massive Gains","url":"https://stock-news.laohu8.com/highlight/detail?id=2517958017","media":"CoinMarketCap","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517958017?lang=en_us&edition=fundamental","pubTime":"2025-03-05 10:29","pubTimestamp":1741141763,"startTime":"0","endTime":"0","summary":"Tezos has been making waves as one of the most underrated smart contract platforms in the crypto space. Unlike Ethereum and Solana, which struggle with congestion and security vulnerabilities, Tezos thrives on on-chain governance and seamless self-amending upgrades. With massive updates coming in March 2025, Tezos is shaping up to be a major player in DeFi and NFTs.Meanwhile, Terra Classic is proving that resilience matters. After facing significant challenges in the past, it has rebounded with a strong community and a renewed focus on stability. By leveraging decentralized governance and DeFi expansion, Terra Classic is securing its place among the most promising blockchain ecosystems in 2025.Then, there’s Qubetics —a blockchain project that’s not just fixing problems but redefining the way blockchain solutions work. With its QubeQode IDE, Qubetics is making blockchain development easier, faster, and more accessible to businesses, professionals, and individuals. Qubetics is quickly be","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://coinmarketcap.com/community/articles/67c7b70482ca1858786d651f/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"coinmarketcap_highlight","symbols":["TON.USD.HKCC","APT.USD.HKCC","ETH.USD.HKCC","SOL.USD.HKCC","APT.USD.CC","TON.USD.CC","SSI","ETH.USD.CC"],"gpt_icon":0},{"id":"2516667488","title":"Nvidia 15% Drop Sets Stage for a Rebound, Analysts Predict","url":"https://stock-news.laohu8.com/highlight/detail?id=2516667488","media":"GuruFocus.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516667488?lang=en_us&edition=fundamental","pubTime":"2025-03-04 21:44","pubTimestamp":1741095888,"startTime":"0","endTime":"0","summary":"March 4 - Bernstein analysts contend that worries over the end of the AI trade are a little premature, maintaining a positive outlook on Nvidia Corporation . In a note, they highlighted that while Nvidia's shares have retreated about 15% year-to-date, the chip giant remains poised for growth amid a new product cycle.The report noted that Nvidia now trades at roughly 25 times next twelve months earnings, its weakest multiple in a year and near a decade low. Analysts led by Stacy A. Rasgon added that the stock is trading below parity relative to the semiconductor index  and only at a slight premium over the S&P 500 levels last seen in 2016.Bernstein pointed to Nvidia's Blackwell product revenues of $11 billion, all shipped in January, as an indicator that supply constraints are easing. They also observed that rising capital expenditure among customers signals robust future demand.Despite regulatory risks, including new AI diffusion rules set for May and potential bans in China, Bernstein","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/nvidia-15-drop-sets-stage-134448801.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1803068979.SGD","LU0985320562.USD","2NVD.UK","LU0048584097.USD","NVDA","LU0345768153.USD","SNVD.UK","LU0528227936.USD","LU2413666699.HKD","LU0345769128.USD","LU2236285917.USD","SSI","LU2361045086.USD","NVD2.UK","LU0345769631.USD","BK4549","LU0787776722.HKD","LU2237438978.USD","SGXZ81514606.USD","LU0354030511.USD","LU0203201768.USD","LU2491050071.SGD","NVD3.UK","SG9999004303.SGD","LU0203202063.USD","LU0109392836.USD","LU2360032135.SGD","NVIW.SI","LU2433249047.HKD","LU2361044949.HKD","NVDU","LU0466842654.USD","LU1721428933.USD","LU2092627202.USD","LU0234572021.USD","LU1815333072.USD","LU1868836914.USD","LU2357305700.SGD","NVDS.UK","NVDS","LU2023250330.USD","LU0868494617.USD","LU2458330243.SGD","3NVD.UK","NVDY","NVDD","LU0345768740.USD"],"gpt_icon":1}],"pageSize":20,"totalPage":10,"pageCount":4,"totalSize":200}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SSI\",params:#limit:5,,,undefined,":[{"market":"US","date":"2019-11-21","symbol":"SSI","fiscalQuarterEnding":"2019/10","expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1574312400000,"reportTimeType":"pre","actualEps":-0.15},{"date":"2019-08-22","symbol":"SSI","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":"2019/07","expectedEps":null,"defaultRemindTime":1566460800000,"name":null,"time":"Pre-Market","dateTimestamp":1566446400000,"actualEps":-0.6},{"market":"US","date":"2019-05-23","symbol":"SSI","fiscalQuarterEnding":"2019/04","expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1558584000000,"reportTimeType":"pre","actualEps":-1.67},{"market":"US","date":"2019-03-07","symbol":"SSI","fiscalQuarterEnding":"2019/01","expectedEps":0.73,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1551934800000,"reportTimeType":"pre","actualEps":0.25},{"market":"US","date":"2018-12-03","symbol":"SSI","amount":0.05,"name":"Stage Stores Inc","currency":"USD","type":"dividend","dateTimestamp":1543813200000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SSI\",market:\"US\",,,undefined,":[{"executeDate":"2017-02-24","recordDate":null,"paymentDate":null,"value":0.15,"currency":"USD"},{"executeDate":"2017-05-25","recordDate":null,"paymentDate":null,"value":0.05,"currency":"USD"},{"executeDate":"2017-08-25","recordDate":null,"paymentDate":null,"value":0.05,"currency":"USD"},{"executeDate":"2017-11-27","recordDate":null,"paymentDate":null,"value":0.05,"currency":"USD"},{"executeDate":"2018-03-05","recordDate":null,"paymentDate":null,"value":0.05,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SSI\",market:\"US\",delay:false,,,undefined,":{}}}